PDCD1 and neoplasm: A study in hepatocellular carcinoma indicates that, apart from the CPS of PD-L1, Wnt/β-catenin activation and CD8+ tumor-infiltrating lymphocyte (TIL) numbers are also conducive in predicting the response to anti-PD-1 antibody treatment (115).